myndfocal — News

Fetching articles…

Latest

Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy

By Xu, State Key Laboratory Of Vascular Homeostasis, Remodeling, Department Of Ultrasound, Peking University Third Hospital, Beijing, Beijing Key Laboratory Of Interdisciplinary Research In Gastrointestinal Oncology, Blgo, Zhang, Song · 2026-03-18

Tumor immunotherapy is often compromised by an immunosuppressive tumor microenvironment (TME) characterized by abnormal vasculature and exhausted T cells. Here, given the role of nitric oxide (NO) in favorably remodeling …

Sustained nitric oxide production by engineered <i>E. coli</i> remodels the tumor microenvironment and potentiates immunotherapy

Politics (9)

STAT+: Senator blasts GSK inhaler practices, calls for reform

STAT+: Two more drugmakers join TrumpRx

STAT+: Pharmalittle: We’re reading about Trump and drug prices, biotechs pushing back, and more

STAT+: Grail CEO steps down after trial setback

STAT+: CMS wants more drugmakers to join Medicaid ‘most-favored nations’ pilot

STAT+: Trump most-favored nation drug pricing deals end after three years for some companies

STAT+: Pharmalittle: We’re reading about Trump’s drug-price claims, a Novo deal for obesity drugs, and more

STAT+: Drugmakers lay out their legal arguments against Trump’s drug pricing experiments

STAT+: Pediatricians confront HHS in vaccine showdown

Technology (3)

STAT+: HHS starts phasing out Anthropic’s Claude

STAT+: How Mayo Clinic’s patients are helping Merck train its AI

FDA relaxes oversight for wellness devices

Business (1)

STAT+: Novo Nordisk strikes deal with U.S. startup to develop oral obesity, diabetes drugs

Health (38)

Sustained nitric oxide production by engineered <i>E. coli</i> remodels the tumor microenvironment and potentiates immunotherapy

STAT+: FDA and NIH announce more initiatives to reduce animal testing in drug development

Biotech news from around the world

STAT+: Judge deals blow to RFK Jr.’s vaccine reforms

<b>One vaccine, no needles, broad protection</b>

Opinion: Congress must pass legislation to ensure Medicare covers breakthrough medical technologies

Fresh turmoil at the FDA with Prasad’s exit

STAT+: A setback for Roche’s breast cancer drug

STAT+: As controversial decisions mount, FDA shuns public advisory meetings

STAT+: Xenon Pharmaceuticals’ seizure drug shows strong efficacy in late-stage trial

STAT+: 5 lessons from Vinay Prasad’s turbulent tenure at the FDA

FDA vaccine head will step down in April after string of controversial decisions

Vinay Prasad, key Makary ally and a focus of controversy at the FDA, is leaving the agency

STAT+: Pharmalittle: We’re reading about an FDA-UniQure tussle, a Pfizer obesity drug approval in China, and more

STAT+: Servier to acquire Day One, maker of pediatric cancer drug, for $2.5B

STAT+: Moderna’s reset hinges on oncology

The FDA, urged to avoid controversy, creates a new headache with attack against UniQure

Breaching the IBD efficacy ceiling, and sham surgeries

Long-term efficacy and safety of the single-dose tetravalent Butantan dengue vaccine

STAT+: Prime Medicine to seek approval for gene-editing treatment after two-patient trial

STAT+: Moderna to pay Roivant up to $2.25 billion to settle patent lawsuit behind mRNA vaccines

In vivo base editing gene therapy for heterozygous familial hypercholesterolemia: a phase 1 trial

STAT+: Pharmalittle: We’re reading about an FDA-UniQure feud, Pfizer’s ‘problem’ with the agency, and more

A titan of vaccine development sees his field’s achievements slip away

Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial

STAT+: Minnesota report shows large hospitals continue to dominate the 340B drug discount program

Kennedy announces new vaccine advisory committee members after meeting rescheduled

Henrietta Lacks’ estate settles with Novartis over the ‘stolen cells’ that advanced science

STAT+: FDA unveils rules for bespoke gene therapies, predicting flood of rare disease applications

STAT+: Nature Medicine to investigate study that found cancer treatment is better in morning

STAT+: Pharmalittle: We’re reading about an FDA official’s speech, a Grail cancer blood test, and much more

Hims’ Super Bowl fallout, and the FDA reverses course

STAT+: What to expect from Gossamer Bio’s late-stage lung disease study

STAT+: NIH Director Bhattacharya to lead CDC after O’Neill’s exit

FDA go-ahead to test cellular rejuvenation therapy in humans

STAT+: New FDA guidance for antibiotic use in food-producing animals prompts criticism over antibiotic resistance

Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy

STAT+: FDA rejects rare disease therapy from Disc Medicine, early recipient of commissioner’s voucher

Entertainment (1)

How STAT would cover ‘The Fugitive’ if its pharma scandal were real

Science (7)

FDA backpedals to review Moderna mRNA flu vaccine

Engineered TnpB genome editors for plants and human cells identified by ribonucleoprotein mutational scanning

Re-evaluating the site-directed nuclease classification as a regulatory trigger for genome-edited plant products

STAT+: Novo reports ‘triple G’ obesity drug study results

STAT+: Novo’s next-gen obesity drug stumbles in Lilly comparison study

Transposable elements in the dark genome

STAT wins fourth Polk Award for reporting on impact of Trump on health

Health & Biotech (12)

STAT+: VC firm Dimension scouting out $700 million for new fund

STAT+: NIH will spend its full budget this year, agency director promises House appropriators

STAT+: Up and down the ladder: The latest comings and goings

Effects of daily multivitamin–multimineral and cocoa extract supplementation on epigenetic aging clocks in the COSMOS randomized clinical trial

STAT+: Up and down the ladder: The latest comings and goings

STAT+: Science Corp. raises $230 million to bring retinal implant to Americans

STAT+: Element Biosciences launches table-top sequencer capable of $100 genome

STAT+: Up and down the ladder: The latest comings and goings

STAT+: In first speech to her FDA staff, Høeg says she’ll scrutinize RSV shots and SSRIs in pregnancy

Trimodal single-cell profiling of transcriptome, epigenome and 3D genome in complex tissues with scHiCAR

Upcoming meeting of federal vaccine panel may be postponed after HHS missed deadlines

STAT+: Up and down the ladder: The latest comings and goings